Paxlovid™
(nirmatrelvir 150 mg tablets | ritonavir 100 mg tablets)

Guide to PAXLOVID packaging

For educational purposes only.

NDA-labeled PAXLOVID

PAXLOVID with original EUA packaging will no longer be authorized for emergency use after March 8, 2024, regardless of the labeled or extended expiration date.

Patients who receive a prescription of EUA-labeled PAXLOVID on or prior to March 8th, and have initiated treatment on or prior to that date, may complete their course of treatment.

EUA=Emergency Use Authorization; NDA=New Drug Application.

Pfizer

For educational purposes only.

Both dose packs will continue to be available in standard dose and reduced dose

NDA-LABELED PAXLOVID PACKAGING

NDA Packaging Recognizable Features:

- Carton is **cube-shaped**
- Carton contains **10 single-dose blister cards**, with each blister card containing 1 dose
- In-Market NDC Numbers:
  - Standard Dose: 0069-5321-30
  - Reduced Dose: 0069-5317-20

CARTON (FRONT)

Standard Dose

Reduced Dose for Patients with **Moderate Renal Impairment**

(eGFR ≥30 mL/min to <60 mL/min)

BLISTER CARD



Standard Dose

This represents 1 of 10 single-dose blister cards.

Reduced Dose for Patients with **Moderate Renal Impairment**

(eGFR ≥30 mL/min to <60 mL/min)

This represents 1 of 10 single-dose blister cards.

Based on the packaging presentation dispensed, counsel patients on how the tablets are labeled on the blister pack, how to take each dose, and how to complete their medication regimen.

eGFR=estimated glomerular filtration rate; NDC=National Drug Code.

Pfizer | Paxlovid™ (nirmatrelvir 150 mg tablets | ritonavir 100 mg tablets)

For educational purposes only.

Other important considerations:

- **PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min) or severe hepatic impairment (Child-Pugh Class C)**
- Patient education may be needed for those who have previously taken a course of PAXLOVID so that they are aware that the packaging for their newly prescribed course may now look different
- Sites are encouraged to return EUA-labeled PAXLOVID as soon as possible; EUA-labeled PAXLOVID cannot be dispensed after March 8, 2024

For more details about commercial use of PAXLOVID, please see the following:

U.S. Government Commercial Transition Guide

See the current Prescribing Information and EUA Fact Sheet for Healthcare Providers for clinically significant drug interactions, including contraindicated drugs. Before prescribing PAXLOVID, please carefully review the patient's current medications to assess for a potential drug interaction with PAXLOVID. You should also inform patients that PAXLOVID may interact with some drugs and is **contraindicated** for use with some drugs; therefore, patients should be advised to communicate the use of any prescription or nonprescription medications or herbal products to their healthcare provider.

Prescribing Information (including BOXED WARNING)

EUA Fact Sheet for Healthcare Providers

PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death; and

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Use the QR codes below to learn more about PAXLOVID

PAXLOVID RESOURCES FOR EMERGENCY AUTHORIZED USE

Find additional **HCP information, including high-risk factors and resources**, at paxlovidhcp.com

Read the Fact Sheet for Healthcare Providers

Find additional **patient information and resources** at paxlovidinformation.com

Read the Fact Sheet for Patients, Parents, and Caregivers

PAXLOVID RESOURCES FOR FDA-APPROVED USE

Find additional **HCP information, including high-risk factors and resources such as the NDA Dosing Guide**, at paxlovid.pfizerpro.com

Read the Prescribing Information

Find additional **patient information and resources** at paxlovid.com

Pfizer | Paxlovid (nirmatrelvir 150 mg tablets | ritonavir 100 mg tablets)